Kiniksa Pharmaceuticals International
KNSA
93.90
+0.36
+0.38%
Kiniksa Pharmaceuticals International
US · KNSA
#1938 by market cap
Listed 2018
93.90
+0.36
+0.38%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $74Market Newswire · 2026/7/13
-
Kiniksa Pharmaceuticals International(KNSA.US) Officer Sells US$14.33 Million in Common StockMarket Newswire · 2026/11/7
-
Rating change
A Quick Look at Today's Ratings for Kiniksa Pharmaceuticals International(KNSA.US), With a Forecast Between $57 to $71Market Newswire · 2026/4/29
-
Rating change
Citi Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $100Market Newswire · 2026/10/15
-
Rating change
Goldman Sachs Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $101Market Newswire · 2026/10/28
-
Kiniksa Pharmaceuticals International(KNSA.US) Officer Sells US$37.4 Million in Common StockMarket Newswire · 2026/11/4
-
Rating change
Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $72Market Newswire · 2026/6/29
-
Kiniksa Pharmaceuticals International(KNSA.US) Officer Sells US$8.94 Million in Common StockMarket Newswire · 2026/11/4
-
Kiniksa Pharmaceuticals International(KNSA.US) Officer Sells US$9.63 Million in Common StockMarket Newswire · 2026/11/4
-
Rating change
A Quick Look at Today's Ratings for Kiniksa Pharmaceuticals International(KNSA.US), With a Forecast Between $87 to $107Market Newswire · 2026/7/30
-
Kiniksa Pharmaceuticals International(KNSA.US) Officer Sells US$3.39 Million in Common StockMarket Newswire · 2026/11/4
-
Rating change
Wells Fargo Initiates Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Announces Target Price $87Market Newswire · 2026/9/30
-
Rating change
Goldman Sachs Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $90Market Newswire · 2026/7/30
-
Rating change
Goldman Sachs Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $75Market Newswire · 2026/7/23
-
Rating change
Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $58Market Newswire · 2026/4/16
-
Rating change
Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $59Market Newswire · 2026/4/29
-
Rating change
J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $122Market Newswire · 2026/10/30
-
Rating change
Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $110Market Newswire · 2026/10/29
-
Rating change
J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $72Market Newswire · 2026/5/4
-
Rating change
CCORF Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $98Market Newswire · 2026/10/30
-
Rating change
Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $53Market Newswire · 2026/2/26
-
Form 144 | Kiniksa Pharmaceuticals International(KNSA.US) Officer Proposes to Sell 4.56 Million in Common StocksMarket Newswire · 2026/10/31
-
Rating change
J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $68Market Newswire · 2026/3/14
-
Form 144 | Kiniksa Pharmaceuticals International(KNSA.US) Officer Proposes to Sell 9.75 Million in Common StocksMarket Newswire · 2026/10/31
-
Rating change
CCORF Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $62Market Newswire · 2026/2/26
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.
Kiniksa Pharmaceuticals International discussion 0 comments